Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

Glenngård, Anna; Hjelmgren, Jonas; Thomsen, Per Hove; Tvedten, Torbjörn

doi:10.3109/08039488.2012.748825

Cited by 28 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, medication choice varies across patients and is often highly individualized. Medication attributes reported to contribute to the attractiveness of specific pharmacotherapies in adults with ADHD include the ability of the medication to improve function during the work day and into the late afternoon and evening, and a reduced number of doses that need to be taken during the day [11]. In addition, as is the case with other chronic disorders [12], medication adherence among adults with ADHD is negatively influenced by multiple factors that include forgetting to take medication (in part due to the executive function deficits that may be associated with ADHD [13]), the complexity of the treatment regimen (e.g.…”

Section: Introductionmentioning

confidence: 99%

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Wigal¹,

Childress

Frick

et al. 2017

Postgraduate Medicine

View full text Add to dashboard Cite

Objectives: Evaluate the efficacy, duration of effect, and safety of 25 mg SHP465 mixed amphetamine salts (MAS) extended-release versus placebo in adults with attention-deficit/hyperactivity disorder (ADHD). Methods: Adults (18-55 years) with ADHD and with ADHD Rating Scale-IV (ADHD-RS-IV) scores ≥24 were randomized to treatment in a double-blind, 2-period, 2-treatment crossover study utilizing the Adult Workplace Environment (AWE), as described by Wigal and Wigal (J Atten Disord 2006;10:92-111). On day 7 of each 7-day treatment period, efficacy was assessed during a 16.5-hour postdose period. The primary endpoint, Permanent Product Measure of Performance (PERMP) total score, was analyzed in the intent-to-treat population using a mixed linear model of analysis of variance. Secondary endpoints, for which the study was not powered, included PERMP problems attempted and answered correctly, ADHD clinician ratings based on counselor observations and inputs during the Time Segment Rating System (Co-ADHD-RS TSRS), and the ADHD self-rating scale (ADHD-SRS). Safety and tolerability assessments included treatment-emergent adverse events (TEAEs) and vital signs. Results: The least squares mean (95% CI) treatment difference (SHP465 MAS-placebo) for PERMP total score significantly favored SHP465 MAS over placebo when averaged across all postdose assessments (19.29 [10.95, 27.63]; P < 0.0001), with significant treatment differences favoring SHP465 MAS over placebo observed at 4-16 hours postdose (all P < 0.01). TEAEs observed with SHP465 MAS (≥5% of participants) included insomnia, decreased appetite, dry mouth, headache, and anorexia. Mean pulse and blood pressure increases with SHP465 MAS exceeded those of placebo. Conclusions: SHP465 MAS (25 mg) was superior to placebo on PERMP total score, with treatment differences observed from 4 to 16 hours postdose; nominal treatment differences on the ADHD-SRS, but not the Co-ADHD-RS TSRS, were also observed. The safety and tolerability profile of SHP465 MAS was similar to previous reports for SHP465 MAS and other long-acting

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Wigal¹,

Childress

Frick

et al. 2017

Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

“…The data also demonstrate that parents would prefer a treatment with equal efficacy but no associated risk of abuse or side effects. Previous studies have reported similar findings, whereby efficacy was regarded as the most important attribute; however, side effects and dosing were also identified as key aspects of treatment [13, 14]. ‘Potential of treatment abuse’ was considered an important attribute by parents of adolescents.…”

Section: Discussionmentioning

confidence: 77%

“…Parents preferred an oral, once-a-day therapy (compared with three times daily administration or a transdermal patch), rapid onset of action, and longer duration of ADHD symptom control. Glenngard et al [13] employed DCE to assess the preferences and willingness to pay of 285 patients with ADHD (or the parents of children and adolescents) for different treatment attributes, including symptom control, side effects, dosing and cost. All attributes were significant predictors of choice ( p < 0.01), with symptom control and side effects considered the most important treatment attributes.…”

Section: Introductionmentioning

confidence: 99%

Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries

Nafees¹,

Setyawan

Lloyd

et al. 2014

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

The objective is to identify attributes of ADHD stimulant medications that influence treatment preferences of parents of children and adolescents with ADHD across six European countries, using a discrete choice experiment (DCE). Different attributes (and associated levels) of stimulant therapies were identified through literature review and clinician input. Attributes included duration and degree of symptom control after each dose, frequency of medication dosing, potential for treatment to be abused, the side effects of vomiting, loss of appetite, and sleep disturbance. Attributes and levels were combined using an orthogonal design to produce a number of discrete hypothetical treatments. Parents were recruited via patient panels in different countries and asked to complete a survey. DCE data were analyzed using conditional logit models to explore the impact of each attribute on participants’ choices. Six hundred individuals (220 parents of adolescents and 380 parents of children) participated. All attributes were significant predictors of choice (p < 0.01). ‘Degree of symptom control’ was the most important attribute whereby the odds of choosing ‘very much improved symptoms’ compared with ‘minimally improved’ was 4.85 [95 % confidence interval (CI) = 4.28–5.49] for the adolescent group and 6.37 (95 % CI = 5.79–7.01) for the child group. Some inter-country differences emerged, e.g., achieving the best degree of symptom control was more important to parents in some countries than others. In conclusion, the study showed that duration and degree of symptom control were the most important aspects of treatment for parents in all countries. The findings revealed cultural differences in the relative importance of attributes.Electronic supplementary materialThe online version of this article (doi:10.1007/s00787-013-0515-6) contains supplementary material, which is available to authorized users.

show abstract

“…However, parents and caregivers value a broad-based approach to ADHD care management [12, 22, 24–27], which often involves school accommodations, parent training, and a pediatric or child psychiatry specialty provider. However, far less is known about preferences for these attributes.…”

Section: Introductionmentioning

confidence: 99%

A Latent Class Analysis to Identify Variation in Caregivers’ Preferences for their Child’s Attention-Deficit/Hyperactivity Disorder Treatment: Do Stated Preferences Match Current Treatment?

Bridges

Ross

et al. 2016

Patient

View full text Add to dashboard Cite

Objectives To investigate variation in caregiver preferences for their child’s attention-deficit/hyperactivity disorder (ADHD) care and to determine if their stated preferences align with current care management. Methods Caregivers of a child aged 4–14 years and in care for ADHD were recruited from pediatric outpatient clinics and advocacy groups across the state of Maryland. Participants completed a survey collecting demographics, the child’s treatment, and caregiver preferences—elicited using a best-worst scaling experiment (case 2). Latent class analysis was used to identify distinct preference segments and bivariate analyses were used to compare the association between segment membership with what the child was currently receiving for their ADHD. Results Participants (n = 184) were predominantly White (68%) and the child’s mother (84%). Most children had ADHD for 2 or more years (79%). Caregiver preferences were distinguished by two segments: continuous medication (36%) and minimal medication (64%). The two groups had very different preferences for when medication was administered (p < 0.001), but they had similar preferences for provider oriented and non-medication interventions (p > 0.05 for the caregiver behavior training, provider communication, provider specialty, and out-of-pocket costs). One third of the sample did not receive the preferred individualized education program and 42% of the minimal medication group reported using medication 7 days a week all year round. Conclusions Although behavior management training and school accommodations aspects of an ADHD care plan are more important to caregivers than evidence-based medication, fewer families had access to educational accommodations. Further research is needed to clarify how stated preferences for care align with treatments used in actual practice settings.

show abstract

Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

Cited by 28 publications

References 12 publications

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment

Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries

A Latent Class Analysis to Identify Variation in Caregivers’ Preferences for their Child’s Attention-Deficit/Hyperactivity Disorder Treatment: Do Stated Preferences Match Current Treatment?

Contact Info

Product

Resources

About